Nuclear medicine is uniquely positioned at the intersection of diagnostics and therapeutics, so should it remain housed with imaging modalities, or stand alone as an independent specialty? Those against independence cite its commonalities with other specialties and the necessity of integrating nuclear medicine into more parts of patient care. Proponents cite the field's specialized workforce, as well as clinical and operational needs, adding that nuclear medicine faces challenges not served by other departments. Are we better within another department, or should we fly solo? Host Ken Herrmann, MD, PhD., is joined by Ora Israel, MD, Martin Pomper, MD, PhD, and Johannes Czernin, MD, to debate the pros and cons of independence. Spoiler alert: every expert on this JNM panel has a different opinion. What's yours?  Listen now!

Thanks to Sofie Biosciences for sponsoring this episode! https://sofie.com/

A popular saying in the nuclear medicine field is that our work spans "from bench to bedside." But the path to get there isn't always clear. Even though there are constant breakthroughs in research and development, the cutting-edge treatments offered by nuclear medicine don't always make it to the patients who need it the most. Barriers within existing healthcare infrastructure, like the workforce pipeline, procedure implementation, and regulatory hurdles all contribute to gaps in patient access to radioligand therapy. But our panel of experts has solutions. In this episode of The JNM Podcast, Ken Hermann, MD, is joined by Vesna Gershan, PhD, Andrei Iagaru, MD, FACNM, FSNMMI, and Uwe Holzwarth, PhD, as they discuss how to increase patient access to nuclear medicine care.

This episode is sponsored by Novartis: https://www.novartis.com/

Before we pop the champagne and count down to 2026, let’s take one last look back at 2025 through our favorite moments in nuclear medicine. Join host Ken Herrmann and his group of “JNM All-Stars:” Tom A. Hope, MD, Irene Buvat, PhD, and Jason S. Lewis, PhD, as they reminisce on their favorite parts of 2025. Tune in before the ball drops!

Data tells us that nuclear medicine has made extraordinary strides in curing prostate cancer, especially with the use of PSMA PET. But how are we reporting on PSMA, and how can this data be standardized globally? SPARC could be the answer! SPARC stands for "Standardized PSMA Reporting Criteria," and it's been initiated because of the widespread use and success of PSMA PET. These guidelines were developed by asking the end-users of PSMA PET reporting what they need and working backwards from there. So what went into this process, and what guidelines may we see going forward? On this episode of The JNM Podcast, host Ken Herrmann talks with Louise Emmett, MD, Anders Bjartell, MD, PhD, FEBU, Michael Morris, MD, and Jochen Walz, MD, about the reporting guidelines that SPARC outlines for nuclear medicine physicians.

This episode is sponsored by the European Association of Urology: https://uroweb.org 

Being able to personalize a patient's treatment is one of the cornerstones of nuclear medicine, but how are we able to do that? PET-Guided radiotherapy is one answer. In addition to staging and defining a disease, PET imaging can also give providers important information about what's going on in the body while a patient is undergoing their treatment regimen. PET can be used to adjust radiotherapy based on changes in the body and disease progression — whether higher doses are needed in areas with more aggressive cancer, or lower, but still effective, doses can be administered to ensure the minimal amount of toxicity to a patient. Join us for this episode of the JNM Podcast as host Ken Herrmann talks with radiotherapy experts Wolfgang Weber and Nancy Lee. Listen on YouTube or wherever you stream podcasts.

This episode is sponsored by GE Healthcare: https://www.gehealthcare.com/products/molecular-imaging

Biomarkers: what are they and how are they useful in the diagnosis and treatment of prostate cancer? On this episode of the JNM Podcast, our panel of experts explores what they call a "liquid biopsy:" using biomarkers shed by cancer cells into the bloodstream to gain vital insights about the disease and its progression, identify candidates who would benefit from certain therapies, and monitor the effectiveness of treatments. Listen now to learn more about the clinical use of biomarkers. Our host Ken Herrmann, MD, is joined by Jake Berchuck, MD, Alexander Wyatt, PhD, and Rana McKay, MD.

This episode is sponsored by Precede Biosciences: https://www.precede.bio/

Is it really happening? Astatine-211 is a promising new radionuclide being further developed and researched for the treatment of cancer. It is a short half-life alpha-emitter that's attracting more interest from the nuclear medicine community as investors take notice of its potential and production capacity improves. So where will 211At be by 2030? And is this a radionuclide that could show up in a clinical setting in the near future? Join host Ken Herrmann, MD with guests Brenda Sandmaier, MD, Tadashi Watabe, MD, and Ferid Haddad PhD, as they discuss the future of this isotope.

This episode is sponsored by IBA Radiopharma Solutions (https://www.iba-radiopharmasolutions.com/) and Accelerate.eu (https://ihi-accelerate.eu/)

In this live episode of The JNM Podcast, Johannes Czernin interviews Anna Karmann to talk about the various career trajectories available in nuclear medicine.

The JNM Podcast is back and live from New Orleans. Guests David Mankoff, Hossein Jadvar, and Todd Peterson answer the question: "Can society-based journals compete with corporate-based publications?"

You love the column, now hear it in person! Throughout the meeting, JNM Editor in Chief Johannes Czernin will host Discussions with Leaders to talk about the most important and exciting topics in nuclear medicine. First up is Richard Wahl, MD.